Transcranial Direct Current Stimulation (tDCS) and Virtual Reality Task in Parkinson Disease
NCT ID: NCT04527809
Last Updated: 2020-08-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
54 participants
INTERVENTIONAL
2019-07-01
2020-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
tDCS for Dual-task Performance in Patients With PD
NCT04504422
Neuromodulation on Motor Function in Parkinson's Disease
NCT02250690
The Impact TDCS-linked Motor and Cognitive Training Gains in Parkinson's Disease
NCT04581590
Effects of Transcranial Direct Current Stimulation on Postural Control
NCT03759132
Transcranial Direct Current Stimulation and Dual Tasks
NCT05871359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants and sampling: Participants will be recruited through referral by the coordinators of places or institutions who has patients available to participate in the state of São Paulo-Brazil.
Inclusion Criteria: Participants with idiopathic Parkinson's Disease, with diagnosis previously confirmed by a specialized doctor, will be included if they have the agreement to participate in the research by signing the informed consent form.
Exclusion Criteria: Participants will be excluded if they used a wheelchair, were unable to complete the procedures due to any reported fatigue or due to having to leave previously, and who could not stand without any kind of help, such as a carrier or walking aids.
Randomization Participants: Participants will be randomly allocated to either group 1 (tDCS-active and VR tasks) or group 2 (tDCS-sham and VR tasks). Randomization will be under the control of a blinded investigator who will be the only person allowed to manage the electronic security file of the randomization to assign the individuals. The investigator will be blind to the group in which the participant is allocated to.
Blinding: The participants, researchers and outcome assessors will remain blind throughout the study. To ensure proper blinding, the researcher responsible for that, will configurate the code of the tDCS device to sham or active before the proper application. It will be no difference between the devices for sham or active application of the tDCS, because the same device has these two options.
Allocation concealment: Allocation concealment will successfully be reached since no one involved in this study (i.e. the participants, researchers, and outcome assessors) will be aware of the treatment allocations.
Intervention
All participants will attend the assigned tDCS and VR intervention as follows: there will be one session of application of tDCS and non-immersive VR tasks during twenty minutes of intervention. The researchers will be trained to perform all interventions tDCS-sham, tDCS-active and VR tasks.
Virtual Reality intervention
During the application of the tDCS-active or sham, it will be performed tasks in non-immersive virtual reality environment to stimulate and verify the performance in the timing coincident task present in the software that will be used provided by the "Bridge Games". A software developed by the Research and Technological Applications in Rehabilitation (Grupo de Pesquisa e Aplicação Tecnológica em Reabilitação - PATER) group of the School of Arts, Sciences, and Humanities of the University of Sao Paulo (EACH-USP).
Heart Rate Variability (HRV): It will be analyzed the HRV when the participant is already in the tDCS-active or sham application + VR task. The HRV analysis will follow the guidelines of the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (TFESC \& NASPE, 1996). The strap (for data collection) will be positioned on the participant's chest, and the Polar RS800cx heart rate receiver will be positioned next to it. HRV will be recorded after the initial assessments at rest for 5 minutes, during virtual reality combined to tDCS training for 10 minutes and for rest after the intervention for 5 minutes, totalizing 20 minutes. For analysis of HRV data at rest 1000 consecutive RR intervals will be used and during the tasks 256 consecutive RR intervals will be used.
HR will be recorded beat by beat throughout the protocol by the Polar RS800CX FC Portable Monitor (Polar Electro, Finland) and RR intervals recorded by the monitor will be transferred to the Polar ProTreiner program (3.0 v., Polar Electro, Finland) , which allows HR visualization and cardiac period extraction in the "txt" file format.
Moderate digital filtering will be performed in the program itself complemented with manual filtering performed in Excel software to eliminate premature ectopic beats and artifacts, and only series with more than 95% sinus beats will be included in the study (Vanderlei et al., 2008).
HRV analysis will be performed using linear (time and frequency domain) and nonlinear methods that will be analyzed using Kubios HRV® software (Kubios HRV v.1.1 for Windows, Biomedical Signal Analysis Group, Department of Applied Physics, University of Kuopio, Finland).
tDCS Intervention
tDCS-active or tDCS-sham will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. The device used will be the DS-Stimulator, from NeuroConn, which allows blindness of the subjects of the research and the experimenters.
Procedure: First, the demarcation and positioning of the tDCS device will be done, and the electrodes positioned at predetermined locations. Anodic TDCS with electrodes between 25-35 cm2, intensity of 2mA, density of up to 0.057 mA / cm2 for a period of 20 minutes will be used. However, for the TDCS-sham (placebo) the same active procedure setting will be used, however, the current will be interrupted after 20 seconds. This configuration will ensure that the electrical stimulus is interrupted before generating considerable stimuli, while the other characteristics of the intervention will be maintained.
After five minutes of stimulation at rest, the individuals performed the VR training with the MoveHero game, first with the upper limbs (during 5 minutes), then with the lower limbs (5 minutes). The participants will have the rest of the time (5 minutes) (with tDCS (sham or active). After each session the participant will be questioned about the presence of adverse effects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
tDCS-active
tDCS-active will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area.
tDCS-active
One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
tDCS-sham
tDCS-sham will be performed over one session during the practice of VR games. The frequency of current applied will be 2mA. The stimulation intensity will be set at 100%, and the anodal electrode will be at the M1 area, and the cathodal electrode at the contralateral supraorbital area. For the TDCS-sham the same active procedure setting will be used, however, the current will be interrupted after 20 seconds. This configuration will ensure that the electrical stimulus is interrupted before generating considerable stimuli, while the other characteristics of the intervention will be maintained.
tDCS-sham
One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tDCS-active
One session of active Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
tDCS-sham
One session of sham Trasncranial Direct Current Stimulation combine to a Virtual Reality task.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Agreement to participate in the research by signing the informed consent form.
Exclusion Criteria
* Unable to complete the procedures due to any reported fatigue.
* Unable to complete the procedures due having to leave previously.
* Could not stand without any kind of help, such as a carrier or walking aids.
40 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sao Paulo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Talita Dias da Silva
Researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Talita D Silva, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Sao Paulo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
School of Arts, Sciences and Humanities of the University of Sao Paulo
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02908218.0.0000.5390
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.